Opiant Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of…
Opiant Pharmaceuticals, Inc. announced that it has signed an agreement with Sanofi to manufacture Opiant’s investigational agent OPNTOO4 (drinabant) for the treatment of Acute…
Read More...
Read More...
